Needham & Company Upgrades ResMed (RMD) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $230.05 +1.46%
Rating Summary:
12 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
12 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Needham & Company analyst Mike Matson upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $180.00.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $153.89 yesterday.
You May Also Be Interested In
- CLSA Upgrades Airport of Thailand PCL. (AOT:TB) (AIPUY) to Outperform (2)
- RBC Capital Upgrades Heidelberg Materials AG (HEI:GR) (HDELY) to Outperform
- UBS Upgrades Voestalpine AG (VOE:AV) (VLPNF) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
